The abstracts presented in this program were originally slated to be presented at the AMCP 2020 meeting in Houston, Texas, April 21-24. The meeting was canceled because of the COVID-19 crisis. In lieu of the scheduled poster presentations, ...
Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database [0.03%]
美国急性髓系白血病病例的经济和临床负担：商业支付者数据库的回顾性分析
Bhavik J Pandya,Chi-Chang Chen,Bruno C Medeiros et al.
Bhavik J Pandya et al.
Background: In the United States, the incidence of acute myeloid leukemia (AML) has steadily increased over the last decade; in 2019, it was estimated that AML would affect 21,450 new patients and lead to 10,920 deaths. D...
A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States [0.03%]
美国临床实践中rurioctocog alfa pegol的回顾性观察研究
Louis Aledort,Scott Milligan,Maureen Watt et al.
Louis Aledort et al.
Background: Research describing patient experience and outcomes with extended half-life recombinant factor VIII (EHL rFVIII) outside of clinical trials is limited. Real-world rFVIII consumption studies, when people with h...
PRACTITIONER UPDATE [0.03%]
实务洞察
Robert B Goldberg
Robert B Goldberg
OBJECTIVE: To review the development and implementation of prescription formularies by managed care organizations, identify their current applications, and recognize future trends in the managed care pharmacy environment. DATA SOURCES: Curr...
Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance [0.03%]
严重感染的发病风险和生物制剂及类似药利用与安全性研究的设计
Jie Zhang,Gayathri Sridhar,Charles E Barr et al.
Jie Zhang et al.
Background: There is a need for postmarketing evidence generation for novel biologics and biosimilars. Objective: To assess the feasibi...
Augmenting Cost-Effectiveness Analysis Will Not Improve Affordability [0.03%]
增强成本效益分析无法改善 affordability问题
John B Watkins,Emily G Tsiao
John B Watkins
No outside funding contributed to this article. The authors are employed by Premera Blue Cross and have nothing to disclose.
Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment [0.03%]
支付意愿及对基因组精准医疗的支付偏好：一项选择试验研究
Devender S Dhanda,David L Veenstra,Dean A Regier et al.
Devender S Dhanda et al.
Background: Although precision medicine using genetic information offers significant promise, its uptake and eventual clinical and economic impacts are uncertain. Health care payers will play an important role in evaluati...
Implementation and Effect of a Pharmacist-to-Pharmacist Transitions of Care Initiative on Ambulatory Care Sensitive Conditions [0.03%]
药师之间的过渡护理计划的实施及其对门诊敏感状况的影响
M Shawn McFarland,Ashley M Thomas,Emily Young et al.
M Shawn McFarland et al.
Background: One of the most vulnerable times in a patient's encounter with a health care system is during transitions of care (TOC), defined by the Joint Commission as the movement of a patient from one health care provid...
Pitfalls of Cost-Effectiveness Analysis in Practice: A TRD Case Example in the United States with Esketamine Versus Oral Antidepressants [0.03%]
成本效益分析实践中的陷阱——美国 esketamine 治疗难治性抑郁症与口服抗抑郁药的案例分析
Swapna Karkare,Hoa H Le,John J Sheehan et al.
Swapna Karkare et al.
The writing of this letter was supported by Janssen Scientific Affairs. The authors are employees of Janssen Scientific Affairs or Janssen Global Services (Johnson & Johnson).
The Authors Respond [0.03%]
作者回复
Daniel R Touchette,Foluso Agboola,Steven J Atlas et al.
Daniel R Touchette et al.
The writing of the original report referred to in this letter was sponsored by the Institute for Clinical and Economic Review (ICER). Agboola, Fazioli, and Pearson are employed by ICER. Touchette reports grants from ICER during the course o...